Integrated Wealth Concepts LLC Acquires 13,850 Shares of Merck & Co., Inc. $MRK

Integrated Wealth Concepts LLC increased its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 12.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 128,068 shares of the company’s stock after purchasing an additional 13,850 shares during the quarter. Integrated Wealth Concepts LLC’s holdings in Merck & Co., Inc. were worth $16,457,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Kingdom Financial Group LLC. bought a new position in Merck & Co., Inc. during the 4th quarter valued at about $25,000. Abound Financial LLC bought a new stake in shares of Merck & Co., Inc. in the fourth quarter worth approximately $26,000. Prosperity Bancshares Inc bought a new stake in shares of Merck & Co., Inc. in the fourth quarter worth approximately $26,000. High Note Wealth LLC grew its stake in shares of Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after acquiring an additional 109 shares during the period. Finally, IFC & Insurance Marketing Inc. purchased a new position in shares of Merck & Co., Inc. during the fourth quarter valued at approximately $31,000. 76.07% of the stock is owned by institutional investors.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrades support valuation: Leerink Partners raised its price target from $127 to $161 and maintained an “outperform” rating, while Guggenheim increased its target from $146 to $170 and assigned a “buy” rating. The revisions suggest analysts see further upside from Merck’s commercial execution and pipeline. Benzinga analyst rating reports
• Positive Sentiment: Pipeline expansion addresses the Keytruda patent cliff: Merck is pairing antibody-drug conjugates (ADCs) with Keytruda in women’s cancers, seeking to improve outcomes in difficult-to-treat tumors while building future revenue sources before Keytruda faces patent pressure. Merck pairs ADCs with Keytruda in women’s cancer push
• Neutral Sentiment: Investor attention is focused on management commentary: Merck presented at the Wells Fargo 21st Annual Healthcare Conference and is scheduled to participate in Morgan Stanley’s global healthcare conference. These events may provide additional detail on Keytruda demand, pipeline progress and long-term growth plans. Wells Fargo healthcare conference transcript
• Neutral Sentiment: Keytruda and new products remain central to the bull case: Commentary highlights Keytruda’s current growth contribution and Merck’s efforts to develop products capable of extending momentum beyond the anticipated 2028 patent cliff. MRK’s strong recent performance and elevated valuation leave expectations high. Merck trading near 52-week high
• Negative Sentiment: Long-term patent risk remains: Investors are watching whether Merck can replace revenue that may be lost when Keytruda’s exclusivity weakens. The company’s ability to commercialize ADC combinations and other pipeline assets is therefore critical to sustaining growth and its current valuation. Merck outlook and GARDASIL commentary

Merck & Co., Inc. Price Performance

NYSE MRK opened at $147.69 on Thursday. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $156.92. The firm has a market capitalization of $364.37 billion, a P/E ratio of 118.15, a PEG ratio of 6.46 and a beta of 0.21. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The company has a 50-day moving average price of $135.91 and a 200-day moving average price of $124.10.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. The company had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm’s revenue was up 5.1% compared to the same quarter last year. During the same quarter last year, the firm posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities research analysts anticipate that Merck & Co., Inc. will post 2.76 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.3%. Merck & Co., Inc.’s payout ratio is presently 272.00%.

Insider Activity

In related news, EVP David R. Maraldo sold 18,706 shares of the firm’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the transaction, the executive vice president directly owned 18,212 shares of the company’s stock, valued at approximately $2,344,248.64. This trade represents a 50.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Chirfi Guindo sold 10,000 shares of Merck & Co., Inc. stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $135.00, for a total value of $1,350,000.00. Following the transaction, the executive vice president owned 36,613 shares in the company, valued at $4,942,755. This trade represents a 21.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 228,238 shares of company stock worth $29,977,783. Company insiders own 0.17% of the company’s stock.

Wall Street Analyst Weigh In

MRK has been the topic of a number of research analyst reports. Argus increased their price objective on shares of Merck & Co., Inc. from $145.00 to $170.00 and gave the company a “buy” rating in a research report on Tuesday, August 25th. Leerink Partners lifted their target price on shares of Merck & Co., Inc. from $127.00 to $161.00 and gave the stock an “outperform” rating in a research report on Wednesday. Jefferies Financial Group lowered shares of Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Royal Bank Of Canada lowered shares of Merck & Co., Inc. from an “outperform” rating to a “sector perform” rating and boosted their target price for the company from $142.00 to $150.00 in a research note on Thursday, August 20th. Finally, Scotiabank increased their price target on Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a report on Tuesday, June 30th. Sixteen analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $150.33.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck’s pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.